Free tool
Oncology stocks
We cover 45 companies grouped under the Oncology theme. The median market value in the group is $73.69M. Across the group, the median move over the past trading day is −0.15%. 39% of the 44 with a 200-day average trade above it. Price change over the past year runs from −77.7% to +52.5% across the middle 80 percent of the group, with a median of −25.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
45 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 132.16 EUR | +14.19% | +47.92% | +91.49% | Oct 29, 2026 |
| MRK | Merck & Co., Inc. | $153.10 | +16.14% | +44.89% | +86.85% | Oct 29, 2026 |
| AZN.L | AstraZeneca PLC | 12,476.00 GBP | −5.00% | −8.20% | +5.65% | Oct 30, 2026 |
| AZN | AstraZeneca PLC | $166.27 | −3.60% | −8.27% | +5.09% | Oct 30, 2026 |
| BMY | Bristol-Myers Squibb Company | $67.57 | +6.24% | +27.70% | +47.01% | Oct 29, 2026 |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | 6,953.00 JPY | −1.64% | −18.35% | +9.21% | Oct 27, 2026 |
| RVMD | Revolution Medicines, Inc. | $215.44 | +17.18% | +172.64% | +466.35% | Nov 4, 2026 |
| ONC | BeOne Medicines AG | $375.80 | +13.72% | +20.83% | +25.21% | Nov 5, 2026 |
| 4568.T | Daiichi Sankyo Company, Limited | 2,874.50 JPY | −0.42% | −17.47% | −17.94% | Oct 30, 2026 |
| BNTX | BioNTech SE | $112.56 | +21.75% | +16.41% | +9.27% | Nov 3, 2026 |
| INCY | Incyte Corporation | $128.12 | −1.39% | +26.33% | +51.01% | Oct 27, 2026 |
| GMAB | Genmab A/S | $33.75 | +16.38% | +6.07% | +36.20% | Nov 5, 2026 |
| 0J9P.L | Incyte Corporation | $129.02 | +1.10% | +29.30% | +53.49% | Oct 27, 2026 |
| GE9.DE | Genmab A/S | 294.20 EUR | +17.26% | +9.78% | −11.12% | Nov 5, 2026 |
| EXEL | Exelixis, Inc. | $56.10 | −0.73% | +28.73% | +45.68% | Oct 27, 2026 |
| 0IJO.L | Exelixis, Inc. | $56.81 | +4.53% | +31.50% | +50.53% | Oct 27, 2026 |
| SMMT | Summit Therapeutics Inc. | $14.23 | +13.39% | −18.78% | −42.63% | Oct 19, 2026 |
| OSE.PA | OSE Immunotherapeutics SA | 3.21 EUR | −0.19% | −39.40% | −47.94% | Sep 28, 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | $4.91 | −9.07% | −40.84% | −13.25% | Nov 13, 2026 |
| 0J4V.L | Heron Therapeutics, Inc. | $0.31 | −3.55% | −76.14% | −78.12% | Nov 3, 2026 |
| OSTX | OS Therapies Incorporated | $1.65 | +10.00% | +23.13% | −34.00% | Nov 16, 2026 |
| CRDF | Cardiff Oncology, Inc. | $0.98 | +20.01% | −63.00% | −54.65% | Nov 12, 2026 |
| PLRX | Pliant Therapeutics, Inc. | $1.16 | +8.41% | −7.20% | −31.36% | Nov 5, 2026 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.31 | +19.09% | +6.50% | −7.75% | Nov 16, 2026 |
| HRTX | Heron Therapeutics, Inc. | $0.31 | −36.29% | −75.22% | −77.04% | Nov 3, 2026 |
| IMMP | Immutep Limited | $0.38 | −2.56% | −87.12% | −77.11% | Sep 2, 2026 |
| 0RAD.L | OSE Immunotherapeutics SA | 3.19 EUR | −1.30% | −39.91% | −48.50% | Sep 28, 2026 |
| CANTA.ST | Cantargia AB (publ) | 1.91 SEK | +3.24% | −53.64% | −27.38% | Nov 25, 2026 |
| HOWL | Werewolf Therapeutics, Inc. | $0.99 | +120.22% | +53.30% | −25.65% | Oct 30, 2026 |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $1.96 | −72.36% | −72.74% | −74.90% | Nov 3, 2026 |
| KYNB | Kyntra Bio, Inc. | $8.11 | +16.20% | −11.52% | −22.66% | Nov 9, 2026 |
| MDNA.TO | Medicenna Therapeutics Corp. | 0.47 CAD | +32.39% | −53.00% | −56.48% | Nov 12, 2026 |
| 4582.T | SymBio Pharmaceuticals Limited | 63.00 JPY | −4.55% | −30.00% | −57.43% | Oct 29, 2026 |
| BYSI | BeyondSpring Inc. | $0.69 | −41.77% | −57.14% | −62.09% | Nov 12, 2026 |
| LTRN | Lantern Pharma Inc. | $2.18 | −16.15% | −29.90% | −46.17% | Nov 11, 2026 |
| CLRB | Cellectar Biosciences, Inc. | $2.54 | +1.60% | −26.80% | −47.30% | Nov 12, 2026 |
| BFRI | Biofrontera Inc. | $1.53 | +37.84% | +111.03% | +77.91% | Nov 11, 2026 |
| TPST | Tempest Therapeutics, Inc. | $1.08 | +24.00% | −63.39% | −89.96% | Nov 5, 2026 |
| LSTA | Lisata Therapeutics, Inc. | $1.74 | +50.00% | −11.22% | −30.40% | Nov 5, 2026 |
| PDSB | PDS Biotechnology Corporation | $0.22 | −67.70% | −73.21% | −82.56% | Nov 12, 2026 |
| BLRX | BioLineRx Ltd. | $2.70 | −3.91% | −3.57% | −26.63% | Aug 31, 2026 |
| LNAI | Lunai Bioworks Inc. | $2.20 | −1.79% | −71.71% | −89.34% | Sep 28, 2026 |
| 0GP7.L | Medivir AB (publ) | 2.03 SEK | +6.77% | +345.66% | +1.60% | Nov 5, 2026 |
| BCAB | BioAtla, Inc. | $3.12 | −11.61% | −88.31% | −86.04% | Nov 12, 2026 |
| CRIS | Curis, Inc. | $1.54 | −68.12% | +57.14% | −5.52% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.